

Thomas L Ortel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/571185/publications.pdf>

Version: 2024-02-01

130
papers

9,469
citations

87888

38
h-index

38395

95
g-index

133
all docs

133
docs citations

133
times ranked

10105
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevention of VTE in Orthopedic Surgery Patients. <i>Chest</i> , 2012, 141, e278S-e325S.	0.8	1,723
2	Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2015, 373, 823-833.	27.0	951
3	Venous Thromboembolism. <i>American Journal of Preventive Medicine</i> , 2010, 38, S495-S501.	3.0	852
4	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Advances</i> , 2020, 4, 4693-4738.	5.2	636
5	Heparin-Induced Thrombocytopenia. <i>New England Journal of Medicine</i> , 2006, 355, 809-817.	27.0	560
6	Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2014, 383, 880-888.	13.7	425
7	14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Autoimmunity Reviews</i> , 2014, 13, 685-696.	5.8	290
8	Crystal structures of the membrane-binding C2 domain of human coagulation factor V. <i>Nature</i> , 1999, 402, 434-439.	27.8	258
9	Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. <i>Nature Genetics</i> , 2000, 26, 106-108.	21.4	237
10	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Autoimmunity Reviews</i> , 2014, 13, 917-930.	5.8	224
11	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2828-2839.	3.8	211
12	Impact of Venous Thromboembolism and Anticoagulation on Cancer and Cancer Survival. <i>Journal of Clinical Oncology</i> , 2009, 27, 4902-4911.	1.6	197
13	Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2012, 157, 796.	3.9	177
14	Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. <i>BMJ: British Medical Journal</i> , 2017, 356, j1065.	2.3	174
15	Topical thrombin and acquired coagulation factor inhibitors: Clinical spectrum and laboratory diagnosis. <i>American Journal of Hematology</i> , 1994, 45, 128-135.	4.1	125
16	Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. <i>Thrombosis Research</i> , 2017, 151, 89-95.	1.7	109
17	Heparin-Induced Thrombocytopenia. <i>Annual Review of Medicine</i> , 2010, 61, 77-90.	12.2	104
18	Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. <i>Blood</i> , 2004, 104, 2783-2790.	1.4	94

#	ARTICLE	IF	CITATIONS
19	Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination—United States, December 2020 to August 2021. <i>Annals of Internal Medicine</i> , 2022, 175, 513-522.	3.9	93
20	Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: A study among a U.S. cohort of commercial insurance enrollees. <i>Thrombosis Research</i> , 2015, 135, 50-57.	1.7	91
21	Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. <i>Blood</i> , 2021, 138, 293-298.	1.4	87
22	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	1.6	80
23	Sex Differences in Platelet Reactivity and Cardiovascular and Psychological Response to Mental Stress in Patients With Stable Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1669-1678.	2.8	78
24	Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A 20-Year Review from the Southern Network on Adverse Reactions (SONAR). <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 845-853.	2.7	77
25	Perioperative management of patients on chronic antithrombotic therapy. <i>Blood</i> , 2012, 120, 4699-4705.	1.4	72
26	ISTH DIC subcommittee communication on anticoagulation in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2138-2144.	3.8	69
27	Familial antiphospholipid antibody syndrome: Criteria for disease and evidence for autosomal dominant inheritance. <i>Arthritis and Rheumatism</i> , 1999, 42, 318-327.	6.7	68
28	Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2008, 100, 678-684.	3.4	68
29	Aspirin Exposure Reveals Novel Genes Associated With Platelet Function and Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1267-1276.	2.8	65
30	Effectiveness of Intermittent Pneumatic Compression Devices for Venous Thromboembolism Prophylaxis in High-Risk Surgical Patients: A Systematic Review. <i>Journal of Arthroplasty</i> , 2016, 31, 524-532.	3.1	65
31	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1490-1501.	3.4	60
32	How I treat catastrophic thrombotic syndromes. <i>Blood</i> , 2015, 126, 1285-1293.	1.4	58
33	Antiphospholipid syndrome: Laboratory testing and diagnostic strategies. <i>American Journal of Hematology</i> , 2012, 87, S75-81.	4.1	55
34	Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2017, 92, 730-738.	4.1	49
35	Parenteral Anticoagulation with the Heparinoid Lomoparan (Org 10172) in Patients with Heparin Induced Thrombocytopenia and Thrombosis. <i>Thrombosis and Haemostasis</i> , 1992, 67, 292-296.	3.4	49
36	Thrombotic Storm Revisited: Preliminary Diagnostic Criteria Suggested by the Thrombotic Storm Study Group. <i>American Journal of Medicine</i> , 2011, 124, 290-296.	1.5	45

#	ARTICLE	IF	CITATIONS
37	Thrombosis and the Antiphospholipid Syndrome. Hematology American Society of Hematology Education Program, 2005, 2005, 462-468.	2.5	41
38	Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism. Thrombosis Research, 2011, 128, 536-540.	1.7	39
39	Acquired thrombotic risk factors in the critical care setting. Critical Care Medicine, 2010, 38, S43-S50.	0.9	33
40	Antifibrinolytic therapy in the management of the kasabach merritt syndrome. American Journal of Hematology, 1988, 29, 44-48.	4.1	31
41	Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. Journal of Thrombosis and Thrombolysis, 2008, 26, 14-21.	2.1	31
42	COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy. Thrombosis Research, 2020, 196, 483-485.	1.7	31
43	Group C Streptococcal Arthritis: Case Report and Review. Clinical Infectious Diseases, 1990, 12, 829-837.	5.8	30
44	Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism. Thrombosis Research, 2015, 136, 535-541.	1.7	30
45	Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation. Hematology American Society of Hematology Education Program, 2009, 2009, 225-232.	2.5	29
46	Clinical causes and treatment of the thrombotic storm. Expert Review of Hematology, 2012, 5, 653-659.	2.2	29
47	Challenges and Priorities for Research. Circulation, 2014, 130, 1192-1203.	1.6	28
48	Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. American Heart Journal, 2018, 195, 108-114.	2.7	28
49	Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. Blood Advances, 2020, 4, 2351-2365.	5.2	26
50	Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2274-2286.	3.8	24
51	The Antiphospholipid Syndrome: What are We Really Measuring? How do We Measure it? And How do We Treat it?. Journal of Thrombosis and Thrombolysis, 2006, 21, 79-83.	2.1	21
52	Bleeding and thrombotic complications of pediatric liver transplant. Pediatric Blood and Cancer, 2018, 65, e26955.	1.5	21
53	Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa. Arthritis and Rheumatism, 1999, 42, 2250-2252.	6.7	20
54	Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. Journal of Thrombosis and Thrombolysis, 2022, 53, 167-175.	2.1	20

#	ARTICLE	IF	CITATIONS
55	Perioperative management of patients on chronic antithrombotic therapy. Hematology American Society of Hematology Education Program, 2012, 2012, 529-535.	2.5	19
56	Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer. EBioMedicine, 2016, 11, 157-164.	6.1	19
57	Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. European Journal of Preventive Cardiology, 2017, 24, 591-599.	1.8	19
58	Bad weed: synthetic cannabinoid-associated coagulopathy. Blood, 2019, 133, 902-905.	1.4	19
59	Effect of intravenous lidocaine on the transcerebral inflammatory response during cardiac surgery: a randomized-controlled trial. Canadian Journal of Anaesthesia, 2016, 63, 1223-1232.	1.6	18
60	Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism. Thrombosis Research, 2015, 135, 659-665.	1.7	16
61	Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. Vox Sanguinis, 2019, 114, 374-385.	1.5	16
62	Thrombocytopenia in association with a wandering spleen. , 1996, 53, 259-263.		15
63	Laboratory Diagnosis of the Lupus Anticoagulant. Current Rheumatology Reports, 2012, 14, 64-70.	4.7	15
64	Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study. American Heart Journal, 2015, 169, 496-507.e1.	2.7	15
65	Perioperative management of patients on chronic antithrombotic therapy. Hematology American Society of Hematology Education Program, 2012, 2012, 529-35.	2.5	13
66	Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized Trial. Blood, 2015, 126, 427-427.	1.4	12
67	Two Instruments to Determine Activated Partial Thromboplastin Time: Implications for Heparin Monitoring. Pharmacotherapy, 1999, 19, 383-387.	2.6	11
68	Associations between positive emotional well-being and stress-induced myocardial ischemia. Journal of Psychosomatic Research, 2017, 93, 14-18.	2.6	11
69	Anticoagulant Therapy in Patients Hospitalized With COVID-19. JAMA Internal Medicine, 2021, 181, 1621.	5.1	11
70	A rare cutaneous manifestation of hemorrhagic bullae to low-molecular-weight heparin and fondaparinux: report of two cases. Journal of Cutaneous Pathology, 2017, 44, 104-106.	1.3	10
71	Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis. Blood Advances, 2020, 4, 500-513.	5.2	10
72	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. Blood Advances, 2021, 5, 4721-4726.	5.2	10

#	ARTICLE	IF	CITATIONS
73	Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency. <i>Thrombosis Research</i> , 2014, 133, 629-633.	1.7	8
74	Prophylactic Dose Low Molecular Weight Heparin (dalteparin) For Treatment Of Vaso-Occlusive Pain Crisis In Patients With Sickle Cell Disease. <i>Blood</i> , 2013, 122, 2241-2241.	1.4	8
75	Thromboprophylaxis for orthopedic surgery; An updated meta-analysis. <i>Thrombosis Research</i> , 2021, 199, 43-53.	1.7	7
76	Subdural Hematoma and Lupus Anticoagulants. <i>Stroke</i> , 1997, 28, 646-648.	2.0	7
77	Evaluation of a rapid and automated heparin-induced thrombocytopenia immunoassay. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 478-484.	1.3	6
78	Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 249-259.	2.1	6
79	Design and Implementation of a Comprehensive Surveillance System for Venous Thromboembolism in a Defined Region Using Electronic and Manual Approaches. <i>Applied Clinical Informatics</i> , 2019, 10, 552-562.	1.7	6
80	A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation. <i>Current Cardiology Reports</i> , 2016, 18, 101.	2.9	5
81	Variants in chondroitin sulfate metabolism genes in thrombotic storm. <i>Thrombosis Research</i> , 2018, 161, 43-51.	1.7	5
82	A Multicenter Randomized Placebo Controlled Trial of Compression Stockings to Prevent the Post-Thrombotic Syndrome After Proximal Deep Venous Thrombosis: The S.O.X. Trial. <i>Blood</i> , 2012, 120, 393-393.	1.4	5
83	Prediction of Heparin Induced Thrombocytopenia: Validation of an Experience-Based Computer Model.. <i>Blood</i> , 2007, 110, 3226-3226.	1.4	5
84	New methods facilitated the process of prioritizing questions and health outcomes in guideline development. <i>Journal of Clinical Epidemiology</i> , 2022, 143, 91-104.	5.0	5
85	Recurrent thrombosis of the superior vena cava associated with activated protein C resistance: imaging findings. <i>Pediatric Radiology</i> , 1998, 28, 597-598.	2.0	4
86	Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. <i>Journal of Clinical Epidemiology</i> , 2021, 138, 115-127.	5.0	4
87	Inhibitory Anti-Factor V Antibodies Bind to the Factor V C2 Domain and Are Associated With Hemorrhagic Manifestations. <i>Blood</i> , 1998, 91, 4188-4196.	1.4	4
88	Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2074-2083.	2.4	4
89	Effect of Heterologous Factor V Heavy Chain Sequences on the Secretion of Recombinant Human Factor VIII. <i>Thrombosis and Haemostasis</i> , 1996, 75, 036-044.	3.4	3
90	Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.. <i>Blood</i> , 2007, 110, 2088-2088.	1.4	3

#	ARTICLE	IF	CITATIONS
91	Inflammation Markers and The Risk Of Post Thrombotic Syndrome: Results From The Bio-Sox Study. <i>Blood</i> , 2013, 122, 36-36.	1.4	3
92	Deficient ADAMTS13 Activity in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura (TTP) in Populations From Japan in 2012: Validation of Findings Initially Reported in the United States in 1998 and 2000.. <i>Blood</i> , 2012, 120, 2203-2203.	1.4	3
93	Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study. <i>Journal of Clinical Apheresis</i> , 2018, 33, 469-479.	1.3	2
94	Equipoise, Trust, and the Need for Cardiologists to Randomly Assign Patients Into Anticoagulation Trials in the Time of COVID. <i>Circulation</i> , 2020, 142, 2296-2298.	1.6	2
95	Meta-analysis and systematic review of randomized controlled trials assessing the role of thromboprophylaxis after vascular surgery. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2022, 10, 767-777.e3.	1.6	2
96	Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial. <i>Blood</i> , 2013, 122, 460-460.	1.4	2
97	The Reliability of Point-of-Care (POC) Prothrombin Time Testing - A Comparison of CoaguChek XSÂ® INR Measurements with Hospital Laboratory Monitoring.. <i>Blood</i> , 2007, 110, 973-973.	1.4	2
98	Clinical implications for patients on antithrombotic therapy while taking supplements. <i>Thrombosis Research</i> , 2005, 117, 75-80.	1.7	1
99	Successful Management of Catastrophic Thrombotic Storm in a Young Boy. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, Publish Ahead of Print, e1132-e1135.	0.6	1
100	Is the use of warfarin becoming obsolete?. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 418-419.	0.8	1
101	15th International Congress on Antiphospholipid Antibodies Task Force on Catastrophic Antiphospholipid Syndrome Report. , 2017, , 307-316.		1
102	Monitoring oral anticoagulant therapy in patients with lupus anticoagulants. <i>British Journal of Haematology</i> , 1998, 101, 390-391.	2.5	1
103	Peripheral Blood Mononuclear Cell Derived Gene Expression Patterns Identify Clinical Phenotypes and Predict Thrombotic Events in Patients with Immune-Mediated Thrombosis.. <i>Blood</i> , 2005, 106, 726-726.	1.4	1
104	Autopsy-Proven Venous Thromboembolism (VTE): Incidence and Characteristics of Patients Correlated with Clinical Management Prior to Death. <i>Blood</i> , 2014, 124, 4257-4257.	1.4	1
105	Heparin Modifies the Immunogenicity of Positively-Charged Proteins.. <i>Blood</i> , 2010, 116, 1435-1435.	1.4	1
106	Prothrombin Complex Concentrates and Cardiac Surgery. <i>Blood</i> , 2015, 126, 4712-4712.	1.4	1
107	OUP accepted manuscript. <i>Cardiovascular Research</i> , 2022, , .	3.8	1
108	Introduction to a review series on COVID-19 and the hematologist. <i>Blood</i> , 2022, 140, 163-164.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Meta-analysis fever in the wake of CARAVAGGIO. Thrombosis Research, 2020, 196, 141-142.	1.7	0
110	Initiation of Efficizumab Therapy in an Adult Patient With Hemophilia A With Inhibitors and Associated Drug Cost Savings. Journal of Pharmacy Technology, 2020, 36, 110-113.	1.0	0
111	A Novel Chemically Induced Fischer F344 Rat Model for Thrombotic Sequelae of Hemolytic Anemias.. Blood, 2004, 104, 3519-3519.	1.4	0
112	Clinical Management and Outcomes of Patients with Heparin/Platelet Factor 4 Antibodies: Retrospective Review at a Single Center.. Blood, 2006, 108, 1053-1053.	1.4	0
113	Gene Expression Patterns Identify Patients with Non-Small Cell Lung Cancer (NSCLC) and Ovarian Cancer Who Are at Increased Risk for Venous Thromboembolism (VTE).. Blood, 2006, 108, 1470-1470.	1.4	0
114	Whole Blood Gene Expression Profiles Distinguish Patients with Single Prior Venous Thromboembolism from Patients with Multiple Prior Events.. Blood, 2007, 110, 1630-1630.	1.4	0
115	Antiphospholipid Syndrome: Clinical Characteristics of Patients and Affected Family Members From Multiplex Families.. Blood, 2009, 114, 2972-2972.	1.4	0
116	Comparison of Thrombin Generation of Sickle Cell Patients in Microparticle Rich and Microparticle Poor Plasma Using Thrombin Generation Assay (TGA).. Blood, 2009, 114, 2557-2557.	1.4	0
117	HIT Antibody Seropositivity and Thromboembolic Events After Cardiac Surgery. Blood, 2011, 118, 1159-1159.	1.4	0
118	Referral Patterns and Outcomes for Women with for Recurrent Pregnancy Loss Managed At a Multidisciplinary Thrombosis Program,. Blood, 2011, 118, 4190-4190.	1.4	0
119	Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin for Elective Surger or Procedure - the BRIDGE Trial: Design, Rationale and Clinical Implications. Blood, 2011, 118, 4327-4327.	1.4	0
120	High Incidence of Antibodies to Protamine and Protamine/Heparin Complexes in Patients Undergoing Cardiopulmonary Bypass. Blood, 2012, 120, 3344-3344.	1.4	0
121	Hypercoagulability in Pediatric Patients with Sickle Cell Disease and Correlation to Transcranial Doppler and Disease Severity. Blood, 2012, 120, 3221-3221.	1.4	0
122	The Effectiveness Of 30-40 Mm Hg Compression Stockings To Treat Acute Leg Pain Associated With Proximal Deep Vein Thrombosis: Results From The Sox Randomized Controlled Trial. Blood, 2013, 122, 1126-1126.	1.4	0
123	Laboratory Assessment of Anti-Coagulant Properties of a Von Willebrand Factor Targeted Aptamer. Blood, 2014, 124, 4279-4279.	1.4	0
124	Venous Thromboembolism (VTE) Surveillance: Incidence, Characteristics, and Initial Treatment of VTE Patients. Blood, 2014, 124, 4256-4256.	1.4	0
125	Risk Factors Associated with 6-Month Recurrent VTE Among Patients in Two Large Population-Based Surveillance Systems. Blood, 2019, 134, 3444-3444.	1.4	0
126	Cancer- Associated Venous Thromboembolism (VTE) Characteristics in Blacks Compared to Whites in Durham County, North Carolina. Blood, 2019, 134, 3652-3652.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Nanoparticle-Directed Targeting of Clustered PSGL-1 Mitigates Neutrophil-Derived Thrombosis in Antiphospholipid Antibody Syndrome. <i>Blood</i> , 2020, 136, 14-15.	1.4	0
128	COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy. <i>Blood</i> , 2020, 136, 23-24.	1.4	0
129	Prevention and treatment of deep venous thrombosis. <i>Vascular</i> , 2008, 16 Suppl 1, S64-70.	0.9	0
130	Introduction to a review series on pediatric hematology. <i>Blood</i> , 0, , .	1.4	0